After a big IPO, Aduro splurges on a Berkeley R&D hub

Aduro Biotech ($ADRO), months removed from a $119 million IPO, is looking to settle down in Berkeley, leasing a four-story R&D complex as it presses forward with a pipeline of cancer treatments. As Berkeleyside reports, the company is planning to move into its new operation in 2016, signing a 12-year lease on a 110,000-square-foot building within the city's biomedical campus. Aduro, led by former UC Berkeley professor Stephen Isaacs, is developing a breakthrough-designated drug combination targeting pancreatic cancer, at the same time working alongside Johnson & Johnson ($JNJ) on some early stage oncology treatments. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.